tiprankstipranks
Trending News
More News >
PRIM, S.A. (ES:PRM)
BME:PRM
Advertisement

PRIM, S.A. (PRM) AI Stock Analysis

Compare
0 Followers

Top Page

ES:PRM

PRIM, S.A.

(BME:PRM)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
€14.00
▲(3.32% Upside)
PRIM, S.A. benefits from a strong technical outlook and a solid financial foundation, despite challenges in profitability and cash flow. The absence of a P/E ratio limits valuation analysis, but the dividend yield offers some appeal. The stock's upward momentum and stable financial position are the most significant factors driving the score.

PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)

PRIM, S.A. Business Overview & Revenue Model

Company DescriptionPrim, S.A., through its subsidiaries, designs, manufactures, and commercializes orthopedic products for physiotherapy, thalassotherapy, hydrotherapy, rehabilitation, spa, geriatrics, and support techniques in Spain and internationally. The company offers products for neuro-trauma, cardiovascular, neuromodulation, operating rooms, endo-surgery, plastic surgery, and ENT. It also engages in management of wellness projects, including hotels, resorts, and club sports. Prim, S.A. was founded in 1870 and is headquartered in Móstoles, Spain.
How the Company Makes MoneyPRIM, S.A. generates revenue through the sale of its electronic components and systems, which are supplied to various industries including automotive, industrial automation, and consumer electronics. The company employs a diversified revenue model consisting of direct sales to original equipment manufacturers (OEMs), long-term supply contracts, and partnerships with other technology firms. Key revenue streams include product sales, licensing agreements for proprietary technologies, and after-sales services such as technical support and maintenance. Additionally, PRM benefits from strategic alliances with industry leaders, which not only expand its market reach but also enhance its product offerings, thereby contributing significantly to its earnings.

PRIM, S.A. Financial Statement Overview

Summary
PRIM, S.A. demonstrates solid revenue growth and a strong balance sheet with low leverage. However, declining profit margins and cash flow challenges indicate areas for improvement. The company should focus on enhancing operational efficiency and cash generation to sustain its growth trajectory.
Income Statement
75
Positive
PRIM, S.A. has shown consistent revenue growth over the years, with a 2.45% increase in the latest year. The company maintains a solid gross profit margin of 48.3%, although it has slightly decreased from the previous year. Net profit margin has also declined to 4.68%, indicating some pressure on profitability. The EBIT and EBITDA margins have decreased, reflecting potential challenges in operational efficiency.
Balance Sheet
80
Positive
The company has a strong balance sheet with a low debt-to-equity ratio of 0.14, indicating prudent financial management and low leverage risk. Return on equity stands at 8.47%, which is reasonable but has decreased from previous years. The equity ratio is healthy, suggesting a stable financial position.
Cash Flow
60
Neutral
Cash flow performance is mixed, with a significant decline in free cash flow growth, indicating potential liquidity challenges. The operating cash flow to net income ratio is below 1, suggesting that not all net income is being converted into cash. However, the free cash flow to net income ratio of 0.49 shows some ability to generate cash relative to net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue240.68M233.15M216.51M197.25M168.51M147.32M
Gross Profit117.99M112.62M45.30M94.56M83.08M74.46M
EBITDA25.26M26.23M28.05M19.71M30.18M15.42M
Net Income14.55M10.92M12.67M8.39M17.42M6.92M
Balance Sheet
Total Assets207.94M190.28M200.10M184.99M179.85M163.64M
Cash, Cash Equivalents and Short-Term Investments13.47M13.75M13.25M14.94M36.54M35.58M
Total Debt17.23M18.50M25.48M22.07M19.07M20.45M
Total Liabilities75.24M61.34M74.28M65.28M58.38M51.90M
Stockholders Equity132.70M128.93M125.82M119.71M121.47M111.74M
Cash Flow
Free Cash Flow25.68M10.76M-20.09M-7.02M13.87M19.56M
Operating Cash Flow36.66M22.11M-11.33M4.89M26.30M25.96M
Investing Cash Flow-10.74M-7.59M-3.67M-14.10M-8.70M-2.06M
Financing Cash Flow-27.67M-11.32M10.46M-12.19M-15.09M3.11M

PRIM, S.A. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.55
Price Trends
50DMA
12.70
Positive
100DMA
12.06
Positive
200DMA
10.94
Positive
Market Momentum
MACD
0.22
Positive
RSI
53.86
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:PRM, the sentiment is Positive. The current price of 13.55 is above the 20-day moving average (MA) of 13.38, above the 50-day MA of 12.70, and above the 200-day MA of 10.94, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:PRM.

PRIM, S.A. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
€225.42M15.913.16%
68
Neutral
€249.91M37.683.04%1.62%0.58%-30.60%
65
Neutral
€668.44M16.443.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
€258.33M-9.43%15.90%37.03%
48
Neutral
€298.06M-4.53%-2.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ES:PRM
PRIM, S.A.
13.55
3.73
38.00%
ES:CBAV
Clinica Baviera
40.30
4.59
12.86%
ES:RJF
LABORATORIO REIG JOFRE
3.03
-0.03
-0.95%
ES:ORY
Oryzon Genomics SA
3.67
1.87
104.34%
ES:ATRY
Atrys Health SA
3.34
-0.06
-1.76%
ES:LAB
Labiana Health SA
4.14
1.66
66.94%

PRIM, S.A. Corporate Events

PRIM, S.A. Updates Syndication Pact Composition
Jun 19, 2025

PRIM, S.A. has announced an expansion and update to the composition of its Syndication Pact, originally formalized on May 15, 2019. This update, communicated by Jorge Prim Martinez, President of the Syndicate, reflects changes agreed upon during the Shareholders’ Assembly meeting held on May 19, 2025, and involves a detailed list of shareholders and their respective shares, totaling 3,162,648 shares or 18.56%.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025